-
公开(公告)号：US11591392B2
公开(公告)日：2023-02-28
申请号：US16697653
申请日：2019-11-27
Applicant: Bristol-Myers Squibb Company
Inventor： Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Huang , Guodong Chen , Michelle Kuhne , Hong-An Truong
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
公开(公告)号：US10533052B2
公开(公告)日：2020-01-14
申请号：US16017489
申请日：2018-06-25
Applicant: Bristol-Myers Squibb Company
Inventor： Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Huang , Guodong Chen , Michelle Kuhne , Hong-An Truong
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
Patent Agency Ranking
23.发明申请公开(公告)号：US20190331694A1
公开(公告)日：2019-10-31
申请号：US16422256
申请日：2019-05-24
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Robert Arch , Jun Zhang , Michelle Mader , Tetsuya Ishino , Joel Bard , William Finlay , Orla Cunningham , Ciara Reilly , Peter Brams , Brigitte Devaux , Haichun Huang , Karla Henning
Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
-
公开(公告)号：US09840562B2
公开(公告)日：2017-12-12
申请号：US14692948
申请日：2015-04-22
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Jing Min , Yanli Wu , Rory F. Finn , Barrett R. Thiele , Wei Liao , Ronald P. Gladue , Arvind Rajpal , Timothy J. Paradis , Peter Brams , Brigitte Devaux , Yi Wu , Kristopher Toy , Heidi N. LeBlanc , Haichun Huang
CPC classification number: C07K16/2878 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/565 , C07K2317/92
Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
-
公开(公告)号：US20160376371A1
公开(公告)日：2016-12-29
申请号：US15195098
申请日：2016-06-28
Applicant: The Rockefeller University , BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jeffrey V. Ravetch , Rony Dahan , Bryan C. Barnhart , Brigitte Devaux , Aaron P. Yamniuk , Shannon L. Okada , Brenda L. Stevens
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/72 , C07K2317/73 , C07K2317/75 , C07K2317/92
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Abstract translation: 本文提供了结合人CD40的激动性抗体或其抗原结合部分。 此类抗体任选地包含对FcγRIIb具有增强的特异性的Fc区。 本发明还提供了通过将本发明的抗体给予有需要的受试者来治疗癌症或慢性感染的方法。
-
公开(公告)号：US20160176963A1
公开(公告)日：2016-06-23
申请号：US14977789
申请日：2015-12-22
Applicant: Bristol-Myers Squibb Company
Inventor： Mark F. Maurer , Tseng-hui Timothy Chen , Brigitte Devaux , Mohan Srinivasan , Susan H. Julien , Paul O. Sheppard , Daniel F. Ardourel , Indrani Chakraborty
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/76 , C07K2317/92 , Y02A50/466
Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.
Abstract translation: 本发明提供了结合人TIGIT（具有Ig和ITIM结构域的T细胞免疫受体）的抗体或其抗原结合片段，以及这些抗体或片段在治疗应用中的用途，例如用于治疗癌症或慢性 病毒感染。 这种治疗方法包括与其它免疫调节受体相互作用的抑制剂如PD-1 / PD-L1相互作用的联合治疗。 本发明还提供了编码抗体的重链和/或轻链可变区的多核苷酸，包含编码抗体的重链和/或轻链可变区的多核苷酸的表达载体，包含载体的细胞，以及制备抗体或 片段通过从细胞表达。
-
27.发明申请TUMOR NECROSIS FACTOR-LIKE LIGAND 1A SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF 有权肿瘤坏死因子类似配体1A特异性抗体及其组合物及其用途公开(公告)号：US20150132311A1
公开(公告)日：2015-05-14
申请号：US14539845
申请日：2014-11-12
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Robert Arch , Jun Zhang , Michelle Madar , Tetsuya Ishino , Joel Bard , William Finlay , Orla Cunningham , Ciara Reilly , Peter Brams , Brigitte Devaux , Haichun Huang , Karla Henning
CPC classification number: G01N33/6863 , C07K16/2875 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
Abstract translation: 本发明提供特异性结合TL1A的抗体或其抗原结合片段。 本发明还提供了获得这样的抗体的方法和编码该抗体的核酸。 本发明还涉及使用这些抗体治疗和/或预防TL1A介导的疾病，病症或病症的组合物和治疗方法。
-
-
-
-
-
-
Search Results
27
records
(took 0.055 seconds)
